Multiple endogenous receptors on ocular surface cells

Multiple endogenous receptors on ocular surface cells is a collective designation for the diverse array of proteins—including G protein-coupled receptors (GPCRs), ion channels, and cytokine receptors—found on the cornea and conjunctiva (Dartt, 2009). These receptors are essential for maintaining the ocular surface's health by regulating tear production, mucin secretion, and inflammatory responses (StatPearls, 'Dry Eye Disease'). In pharmaceutical development, this term is frequently used in regulatory documentation, such as FDA labels for drugs like Miebo (perfluorohexyloctane) and Vevye (cyclosporine), to specify that a therapeutic agent acts through physical or mechanical means rather than through direct biochemical interaction with these cellular receptors (FDA Label, Miebo, 2023). For drugs that do target these receptors, such as secretagogues or anti-inflammatories, the goal is typically to restore the homeostatic balance of the tear film or reduce pathological inflammation. For example, Varenicline (Tyrvaya) targets nicotinic acetylcholine receptors on the ocular surface and nasal mucosa to stimulate natural tear production (Tyrvaya Prescribing Information). Other agents like Pilocarpine or Brimonidine interact with muscarinic or adrenergic receptors, respectively, to manage conditions like glaucoma or dry eye. Understanding this collective target is crucial for distinguishing between mechanical lubricants and pharmacologically active agents in the treatment of ocular surface diseases.

Other names

Ocular surface receptorsCorneal and conjunctival receptorsEndogenous ocular receptors

Modulation of ocular homeostasis through agonism or antagonism of specific surface receptors (e.g., muscarinic, adrenergic, nicotinic), or the provision of physical barriers to prevent evaporation in the absence of receptor binding.